Subscribe

Wayne Kuznar

Authored Articles

New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
NCCN, Leukemia, Lymphoma, NCCN 2023 Conference Highlights, Hematologic Malignancies
June 2023, Vol 14, No 3 - Online Only
Read Article
Optimal Systemic Therapy for Renal Cell Carcinoma Is Still Evolving
Wayne Kuznar
NCCN, NCCN 2023 Conference Highlights, Renal-Cell Carcinoma, Genitourinary Cancers
June 2023, Vol 14, No 3 - Online Only
Read Article
Addressing Health Equity in Bladder Cancer Care
Wayne Kuznar
ASCO GU 2023 HIGHLIGHTS, Bladder Cancer, Genitourinary Cancers
April 2023, Vol 14, No 2
Read Article
What Will It Take to End Cancer As We Know It?
Wayne Kuznar
ASCO GU 2023 HIGHLIGHTS
April 2023, Vol 14, No 2
Read Article
Choosing Adjuvant Treatment for Patients with RCC Requires Careful Consideration of Risks and Benefits
Wayne Kuznar
ASCO GU 2023 HIGHLIGHTS, Renal-Cell Carcinoma, Genitourinary Cancers
April 2023, Vol 14, No 2
Read Article
Survey Results Provide Insights into Biosimilar Use at Cancer Centers
Wayne Kuznar
Biosimilars, ASCO 2022 Highlights
February 2023, Vol 14, No 1
Read Article
Dexamethasone-Sparing Regimen Safe and Effective in Frail Patients with Multiple Myeloma
Wayne Kuznar
ASH Highlights, Multiple Myeloma
February 2023, Vol 14, No 1
Read Article
CTC Count May Help Physicians Choose Treatment for Patients with Metastatic Breast Cancer
Wayne Kuznar
SABCS Highlights, Breast Cancer
February 2023, Vol 14, No 1
Read Article
Biosimilar Substitution May Reduce Financial Risk to Providers in Value-Based Payment Models
Wayne Kuznar
Biosimilars, ASCO 2022 Highlights
February 2023, Vol 14, No 1
Read Article
Experts Discuss Current and Future State of Value-Based Agreements
Wayne Kuznar
AVBCC 2022 Summit
December 2022, Vol 13, No 6
Read Article
Increased Biosimilar Use Translates to Substantial Savings for Oncology Practices
Wayne Kuznar
Biosimilars
October 2022, Vol 13, No 5
Read Article
Adding Pembrolizumab to Chemotherapy Extends Survival in Women with Cervical Cancer Across Several Key Subgroups
Wayne Kuznar
Cervical Cancer
October 2022, Vol 13, No 5
Read Article
CAR T-Cell Effective as Second-Line Treatment in Transplant-Ineligible Large B-Cell Lymphoma
Wayne Kuznar
Hematologic Malignancies
October 2022, Vol 13, No 5
Read Article
ASCO President Stresses the Importance of Innovation for Advancing Equitable Cancer Care
Wayne Kuznar
Healthcare Equity
August 2022, Vol 13, No 4 Online Only
Read Article
Trastuzumab Deruxtecan Is a New Standard of Care for Patients with HER2-Low Metastatic Breast Cancer
Wayne Kuznar
ASCO 2022 Highlights, Breast Cancer
August 2022, Vol 13, No 4 Online Only
Read Article
Darolutamide plus ADT and Docetaxel Improves Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer
Wayne Kuznar
Prostate Cancer
June 2022, Vol 13, No 3
Read Article
Updates to Screening and Surveillance Recommendations for Colorectal Cancer
Wayne Kuznar
NCCN Conference Highlights
June 2022, Vol 13, No 3
Read Article
The Role of Telehealth in the Delivery of Cancer Care: Exploring Ongoing Opportunities and Challenges
Wayne Kuznar
NCCN Conference Highlights
June 2022, Vol 13, No 3
Read Article
Nivolumab plus Ipilimumab Shows Promising Activity in the Neoadjuvant Setting for Patients with MSI/dMMR Oeso-Gastric Adenocarcinoma
Wayne Kuznar
Gastrointestinal Cancers
June 2022, Vol 13, No 3
Read Article
Continuous Enzalutamide Reduces Risk for Progression in Patients with Metastatic Castration-Resistant Prostate Cancer
Wayne Kuznar
ASCO GU 2022 Highlights
April 2022, Vol 13, No 2
Read Article
Exploring the Future of Genetic Therapies and Value-Based Care in Oncology
Wayne Kuznar
AVBCC 2021 Summit
April 2022, Vol 13, No 2
Read Article
Novel Vaccine plus Chemotherapy Shows Promise in the Treatment of Metastatic Pancreatic Cancer
Wayne Kuznar
ASCO GI 2022 Highlights
April 2022, Vol 13, No 2
Read Article
Community-Based Providers Focus on Optimal Delivery of Care Despite Ongoing Challenges
Wayne Kuznar
AVBCC 2021 Summit
April 2022, Vol 13, No 2
Read Article
Pembrolizumab Added to Best Supportive Care Extends Survival in Advanced HCC
Wayne Kuznar
ASCO GI 2022 Highlights
April 2022, Vol 13, No 2
Read Article
AK104 plus Chemotherapy Shows Promise in Patients with Advanced Gastric Cancers
Wayne Kuznar
ASCO GI 2022 Highlights
April 2022, Vol 13, No 2
Read Article
Neoadjuvant Enfortumab Vedotin Appears Promising in Patients with Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin
Wayne Kuznar
ASCO GU 2022 Highlights
April 2022, Vol 13, No 2
Read Article
Neoadjuvant Checkpoint Inhibitor plus TKI for Localized Renal-Cell Carcinoma: Encouraging Disease-Free Survival
Wayne Kuznar
ASCO GU 2022 Highlights
April 2022, Vol 13, No 2
Read Article
Mosunetuzumab Induces Deep Remissions in Patients with Relapsed/Refractory Follicular Lymphoma
Wayne Kuznar
ASH Highlights
February 2022, Vol 13, No 1 Online Only
Read Article
Results from 2 Studies Provide Insights on Antibody Response to COVID-19 Vaccines in Patients with Hematologic Malignancies
Wayne Kuznar
ASH Highlights
February 2022, Vol 13, No 1 Online Only
Read Article
CAR T-Cell Therapies Show Efficacy in Second-Line Treatment of Large B-Cell Lymphoma
Wayne Kuznar
ASH Highlights
February 2022, Vol 13, No 1 Online Only
Read Article
Oncology Pipeline Overview: Recent Approvals and Near-Term Drugs
Wayne Kuznar
AVBCC 2021 Summit
February 2022, Vol 13, No 1 Online Only
Read Article
Support Services for Patients with Cancer Must Go Beyond Simply Building a HUB
Wayne Kuznar
AVBCC 2021 Summit
February 2022, Vol 13, No 1 Online Only
Read Article
Drug Price Reform with Value in Mind: Is It Possible?
Wayne Kuznar
AVBCC 2021 Summit
December 2021, Vol 12, No 6
Read Article
The Impact of Telehealth on Quality, Access, and Cost in Cancer Care
Wayne Kuznar
AVBCC 2021 Summit
December 2021, Vol 12, No 6
Read Article
Biosimilars and the Road Ahead
Wayne Kuznar
AVBCC 2021 Summit
December 2021, Vol 12, No 6
Read Article
Balstilimab Shows Promise in the Treatment of Advanced Cervical Cancer
Wayne Kuznar
Cervical Cancer
October 2021, Vol 12, No 5
Read Article
New Saliva Test Can Detect HPV-Associated Head and Neck Cancer
Wayne Kuznar
Head and Neck Cancer
October 2021, Vol 12, No 5
Read Article
ASCO 2021 Presidential Address: Eliminating Disparities in Cancer Care
Wayne Kuznar
ASCO 2021 Highlights, Disparities in Cancer Care
August 2021, Vol 12, No 4
Read Article
New CAR T-Cell Therapy Produces Durable Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Multiple Myeloma
August 2021, Vol 12, No 4
Read Article
Novel LAG-3–Blocking Antibody plus Nivolumab Shows Promise as First-Line Treatment in Advanced Melanoma
Wayne Kuznar
ASCO 2021 Highlights, Melanoma
August 2021, Vol 12, No 4
Read Article
Early Phase 3 Results Show Survival Benefit with Nivolumab-Based Regimens in Advanced Esophageal Squamous-Cell Cancer
Wayne Kuznar
Gastrointestinal Cancers, ASCO 2021 Highlights
August 2021, Vol 12, No 4
Read Article
Maintenance with PARP Inhibitors Extends Survival in Patients with Advanced Ovarian Cancer
Wayne Kuznar
Ovarian Cancer
June 2021, Vol 12, No 3
Read Article
Bemarituzumab, FGFR2b Inhibitor, Improves Survival in Advanced Gastric Cancer with FGFR2b Mutation
Wayne Kuznar
ASCO 2021 Highlights
April 2021, Vol 12, No 2
Read Article
First CD73 Inhibitor Induces Responses in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Wayne Kuznar
ASCO 2021 Highlights, Breast Cancer
April 2021, Vol 12, No 2
Read Article
Zanidatamab Shows Promising Activity in Patients with HER2-Overexpressing Gastric Cancers
Wayne Kuznar
ASCO 2021 Highlights
April 2021, Vol 12, No 2
Read Article
Final Results from ClarIDHy: Ivosidenib Extends Survival in Patients with Cholangiocarcinoma and IDH1 Mutation
Wayne Kuznar
ASCO 2021 Highlights, Cholangiocarcinoma
April 2021, Vol 12, No 2
Read Article
ASH 2020 Presidential Symposium Highlights Innovations Aimed to Improve Patient Access to Treatment
Wayne Kuznar
Value-Based Care
February 2021, Vol 12, No 1
Read Article
Pevonedistat plus Azacitidine Combination Improves Outcomes versus Azacitidine Monotherapy in High-Risk Myelodysplastic Syndromes
Wayne Kuznar
Myelodysplastic Syndromes
February 2021, Vol 12, No 1
Read Article
Magrolimab, First CD47 Antibody, Shows Promise in Combination with Azacitidine in Unfit Patients with Acute Myeloid Leukemia
Wayne Kuznar
Emerging Therapies
February 2021, Vol 12, No 1
Read Article
Oral Azacitidine Extends Survival in Acute Myeloid Leukemia, Regardless of MRD Status, in Patients in Remission After Chemotherapy
Wayne Kuznar
Leukemia
February 2021, Vol 12, No 1
Read Article
Umbralisib plus Ublituximab Combination Superior to Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia
Wayne Kuznar
Leukemia
February 2021, Vol 12, No 1
Read Article
Bispecific Antibodies in Phase 1 Studies Show Promising Efficacy in Heavily Pretreated Patients with Multiple Myeloma
Wayne Kuznar
Multiple Myeloma
February 2021, Vol 12, No 1
Read Article
Belantamab Induces Deep Responses in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Multiple Myeloma
February 2021, Vol 12, No 1
Read Article
Novel Combinations Achieving Undetectable Minimal Residual Disease in Patients with CLL
Wayne Kuznar
NCCN 2020 Hematologic Malignancies
December 2020, Vol 11, No 6
Read Article
Dual RAF/MEK Inhibitor Shows Promising Activity in Tumors with RAS/RAF Mutations
Wayne Kuznar
Emerging Therapies
December 2020, Vol 11, No 6
Read Article
Changes to the Oncology Care Model Spurred by the COVID-19 Pandemic
Wayne Kuznar
Oncology Care Model
December 2020, Vol 11, No 6
Read Article
AACR’s Cancer Disparities Inaugural Report Addresses Care Inequities
Wayne Kuznar
Disparities in Cancer Care
October 2020, Vol 11, No 5
Read Article
Can We Lower the Cost of Cancer Care?
Wayne Kuznar
Value-Based Care
October 2020, Vol 11, No 5
Read Article
Opportunities for Innovation in Value-Based Payments in Oncology
Wayne Kuznar
Value-Based Care
October 2020, Vol 11, No 5
Read Article
ASCO 2020 Presidential Address: Accelerating Progress, Prioritizing Diversity
Wayne Kuznar
Value-Based Care
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Read Article
Adjuvant Osimertinib a Practice-­Changing Treatment in Early-Stage NSCLC with EGFR Mutation
Wayne Kuznar
Lung Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Read Article
Capmatinib Shows Activity in MET-Amplified Non–Small-Cell Lung Cancer
Wayne Kuznar
Lung Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Read Article
Tumor-Infiltrating Lymphocyte Therapy Induces Responses Across Wide Range of Patients with Advanced Melanoma
Wayne Kuznar
Emerging Therapies
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Read Article
The WEE1 Inhibitor Adavosertib Displays Promising Clinical Activity in Uterine Serous Cancer
Wayne Kuznar
Emerging Therapies
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Read Article
Olaparib Extends Survival by >1 Year in Patients with Ovarian Cancer and BRCA Mutation, Ushering in Personalized Medicine in This Malignancy
Wayne Kuznar
Ovarian Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Read Article
Pembrolizumab Added to First-Line Chemotherapy Improves Progression-Free Survival in Metastatic TNBC
Wayne Kuznar
Breast Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Read Article
Nivolumab plus Ipilimumab May Be a New First-Line Option for Patients with MSI-H or dMMR Metastatic Colorectal Cancer
Wayne Kuznar
Colon Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Read Article
Axicabtagene Ciloleucel Induces Durable Responses in Advanced Follicular and Marginal-Zone Lymphoma
Wayne Kuznar
Leukemia, Lymphoma
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Read Article
Early Detection of Cancer Feasible with Blood-Based Tests
Wayne Kuznar
Value-Based Care
June 2020, Vol 11, No 3
Read Article
Bispecific CAR T-Cells Show Promise in Children and Young Adults with Relapsed B-Cell ALL
Wayne Kuznar
AACR Meeting Highlights
June 2020, Vol 11, No 3
Read Article
Two Ways to Target Tumors with KRAS Mutations
Wayne Kuznar
AACR Meeting Highlights
June 2020, Vol 11, No 3
Read Article
Androgen-Deprivation Therapy Seldom Used with Radiation in Localized Prostate Cancer
Wayne Kuznar
Prostate Cancer
June 2020, Vol 11, No 3
Read Article
Atezolizumab-Bevacizumab Combo Improves Survival and Quality of Life in Unresectable Liver Cancer
Wayne Kuznar
Gastric Cancer
June 2020, Vol 11, No 3
Read Article
Promising 3-Drug Regimen for Advanced Gastric Cancer, Regardless of PD-L1 Expression
Wayne Kuznar
Gastric Cancer
June 2020, Vol 11, No 3
Read Article
Universal CAR T-Cells a Promising Off-the-Shelf Therapy for T-Cell ALL
Wayne Kuznar
Value-Based Care
June 2020, Vol 11, No 3
Read Article
NCCN Issues Guidance for Cancer Care During the COVID-19 Pandemic
Wayne Kuznar
COVID-19
April 2020, Vol 11, No 2
Read Article
De-escalating Chemotherapy Possible in Low-Risk Patients with Advanced Testicular Cancer
Wayne Kuznar
ASCO, Genitourinary Cancers
April 2020, Vol 11, No 2
Read Article
A Call to Focus on Financial Toxicity and Quality of Life in Genitourinary Malignancies
Wayne Kuznar
ASCO, Genitourinary Cancers
April 2020, Vol 11, No 2
Read Article
MicroRNAs Have Promise as Biomarker in Testicular and Other Germ-Cell Tumors
Wayne Kuznar
ASCO, Genitourinary Cancers
April 2020, Vol 11, No 2
Read Article
Cabozantinib–Atezolizumab Combination Shows Activity in Difficult-to-Treat Prostate Cancer
Wayne Kuznar
Prostate Cancer
April 2020, Vol 11, No 2
Read Article
ASCO Updates Its Oncology Medical Home Payment Model, Putting Patient Needs Up Front
Wayne Kuznar
Value-Based Care
April 2020, Vol 11, No 2
Read Article
Gemcitabine-Cisplatin Combination a New Standard in Pancreatic Cancer with Germline BRCA or PALB2 Mutation
Wayne Kuznar
ASCO, Gastrointestinal Cancers, Pancreatic Cancer
April 2020, Vol 11, No 2
Read Article
Encorafenib plus Cetuximab Improves Quality of Life versus Standard of Care in Colorectal Cancer Associated with BRAF Mutation
Wayne Kuznar
ASCO, Colorectal Cancer, Gastrointestinal Cancers
April 2020, Vol 11, No 2
Read Article
Investigational Oral Form of Azacitidine Improves Survival as Maintenance Therapy in Patients with Acute Myeloid Leukemia
Wayne Kuznar
Leukemia, Personalized Medicine
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Read Article
First-Line Acalabrutinib-Based Triplet Therapy Leads to Undetectable Minimal Residual Disease in CLL
Wayne Kuznar
Leukemia, Personalized Medicine
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Read Article
Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy May Prevent Cytokine Release Syndrome
Wayne Kuznar
Emerging Therapies
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Read Article
Nivolumab Monotherapy as Bridge to Transplant in Patients with Relapsed or Refractory Hodgkin Lymphoma
Wayne Kuznar
Lymphoma, Personalized Medicine
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Read Article
All-Oral Time-Limited Combination Treatment for CLL or SLL Shows Early Impressive Efficacy
Wayne Kuznar
Leukemia, Personalized Medicine
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Read Article
Investigational BET Inhibitor, CPI-0610, Promotes Responses in Myelofibrosis
Wayne Kuznar
Myelofibrosis
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Read Article
Advances in Cellular Therapies for Hematologic Malignancies Highlighted at ASH 2019
Wayne Kuznar
ASH Highlights
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Read Article
Pemigatinib Effective in Patients with Cholangiocarcinoma and FGFR2 Fusion or Rearrangement
Wayne Kuznar
Cholangiocarcinoma
December 2019, Vol 10, No 6
Read Article
Practice-Changing Results: Ivosidenib First Targeted Therapy to Show Benefits in Patients with Cholangiocarcinoma and IDH1 Mutation
Wayne Kuznar
Cholangiocarcinoma
December 2019, Vol 10, No 6
Read Article
Pembrolizumab as a First-Line Standard-of-Care Option in Advanced Non–Small-Cell Lung Cancer
Wayne Kuznar
Lung Cancer, Solid Tumors, Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Noninvasive Molecular Diagnosis Using Circulating DNA Sequencing Improves Outcomes in Cholangiocarcinoma Management
Wayne Kuznar
Cholangiocarcinoma
October 2019, Vol 10, No 5
Read Article
Neoantigens Are Effective Targets for Developing Cancer Vaccines
Wayne Kuznar
October 2019, Vol 10, No 5
Read Article
Selective, Small-Molecule DRD2 Antagonist Induces Tumor Regression in Recurrent High-Grade Glioma
Wayne Kuznar
Emerging Therapies, Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Read Article
Autologous Mesothelin-Targeted T-Cells Induce Responses in Pleural Solid Tumors
Wayne Kuznar
Emerging Therapies, Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Read Article
Gilteritinib and CX-01 in the Treatment of Patients with Acute Myeloid Leukemia
Wayne Kuznar
Leukemia, Hematologic Malignancies, Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Read Article
The Pediatric MATCH Study: Actionable Targets Found in 25% of Young Patients with Cancer
Wayne Kuznar
Pediatric Cancer, Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Read Article
BLU-667, Selective RET Inhibitor, Demonstrates Antitumor Activity in NSCLC with RET Fusion
Wayne Kuznar
Lung Cancer, Solid Tumors, Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Read Article
Repotrectinib, an Investigational TKI, Elicits Responses in Patients with Advanced NSCLC and ROS1 Alterations
Wayne Kuznar
Lung Cancer, Solid Tumors, Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Read Article
Personalized Neoadjuvant Immunotherapy Combinations Improve Outcomes in Stage III Melanoma
Wayne Kuznar
Melanoma
June 2019, Vol 10, No 3
Read Article
Adding PARP Inhibitor to Immune Checkpoint Blockade Improves Responses in Ovarian Cancer with BRCA Mutations
Wayne Kuznar
Ovarian Cancer
June 2019, Vol 10, No 3
Read Article
Can Immunotherapy Work in Ovarian Cancer?
Wayne Kuznar
Immunotherapy, Ovarian Cancer, Personalized Medicine
June 2019, Vol 10, No 3
Read Article
Revised Risk Categories in NCCN Guideline for Metastatic Renal-Cell Carcinoma Affects Preferred Front-Line Options
Wayne Kuznar
2019 NCCN Conference
June 2019, Vol 10, No 3
Read Article
Updated NCCN Guideline Strongly Recommends Germline Testing for All Patients with Pancreatic Cancer
Wayne Kuznar
2019 NCCN Conference, Pancreatic Cancer
June 2019, Vol 10, No 3
Read Article
New Targeted Therapies for Metastatic Colorectal Cancer Recommended in the Updated NCCN Guideline
Wayne Kuznar
2019 NCCN Conference
June 2019, Vol 10, No 3
Read Article
Assessment of Opioid Misuse and Abuse Should Be Part of Cancer Pain Management
Wayne Kuznar
2019 NCCN Conference
June 2019, Vol 10, No 3
Read Article
Expert Panel Discusses Access to CAR T-Cell Therapy
Wayne Kuznar
2019 NCCN Conference
June 2019, Vol 10, No 3
Read Article
Evolving Immuno-Oncology Strategies in Renal-Cell Carcinoma
Wayne Kuznar
Immunotherapy, Renal-Cell Carcinoma, Personalized Medicine
June 2019, Vol 10, No 3
Read Article
Durvalumab plus Tremelimumab Immunotherapy Combination Extends Survival in Refractory Colorectal Cancer
Wayne Kuznar
Immunotherapy, Personalized Medicine
June 2019, Vol 10, No 3
Read Article
Updated NCCN Treatment Guideline for CML Establishes Criteria for Stopping TKI Therapy
Wayne Kuznar
2019 NCCN Conference, Leukemia, Hematologic Malignancies
April 2019, Vol 10, No 2
Read Article
SM-88, a Novel Tumor Metabolism–Altering Regimen, Shows Promise as Third-Line Therapy for Metastatic Pancreatic Cancer
Wayne Kuznar
GI Cancers Symposium
April 2019, Vol 10, No 2
Read Article
Triple-Drug Regimen Improves Survival in Metastatic Colorectal Cancer with BRAF V600E Mutation
Wayne Kuznar
GI Cancers Symposium
April 2019, Vol 10, No 2
Read Article
Adjuvant Therapy with Durvalumab Shows Promise in Advanced Esophageal Cancer
Wayne Kuznar
GI Cancers Symposium
April 2019, Vol 10, No 2
Read Article
CAR T-Cell Therapy Associated with Unique, Acute Adverse Events Requiring Vigilant Monitoring
Wayne Kuznar
Immunotherapy, Personalized Medicine
April 2019, Vol 10, No 2
Read Article
Genomic Markers of Response Improve Patient Selection for Immune Checkpoint Inhibitor Therapy
Wayne Kuznar
Immunotherapy, Personalized Medicine
April 2019, Vol 10, No 2
Read Article
Sacituzumab, a Novel Antibody-Drug Conjugate, Shows Activity in Heavily Pretreated Urothelial Cancer
Wayne Kuznar
Genitourinary Cancers Symposium
April 2019, Vol 10, No 2
Read Article
Immunotherapy Moving into Earlier Lines of Lung Cancer Therapy
Wayne Kuznar
Lung Cancer, Solid Tumors, Personalized Medicine
April 2019, Vol 10, No 2
Read Article
Updated NCCN Breast Cancer Guideline Expands Treatment Recommendations for HR-Positive, HER2-Negative Disease
Wayne Kuznar
2019 NCCN Conference, Breast Cancer
April 2019, Vol 10, No 2
Read Article
Immunotherapy Strategies in the Updated NCCN Guideline for NSCLC Hinge on PD-L1 Testing
Wayne Kuznar
2019 NCCN Conference
April 2019, Vol 10, No 2
Read Article
Personalizing Immunotherapy in NSCLC Using PD-L1 and Tumor Mutation Burden as Biomarkers
Wayne Kuznar
Immunotherapy, Lung Cancer, Solid Tumors, Personalized Medicine
April 2019, Vol 10, No 2
Read Article
CAR T-Cell Therapy Fills Unmet Needs in Leukemia and Lymphoma
Wayne Kuznar
Immunotherapy, Leukemia, Lymphoma, Hematologic Malignancies, Personalized Medicine
April 2019, Vol 10, No 2
Read Article
Adding Pegylated Interferon to Nilotinib Enhances Molecular Response in Chronic-Phase Chronic Myeloid Leukemia
Wayne Kuznar
Leukemia, FDA Approvals, News & Updates, Hematologic Malignancies
Web Exclusives
Read Article
Rapid Progress in Aggressive Hematologic Malignancies Highlighted at ASH 2018
Wayne Kuznar
Hematologic Malignancies
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
Read Article
Next-Generation BTK Inhibitor Highly Active in Relapsed or Refractory Mantle-Cell Lymphoma
Wayne Kuznar
Lymphoma
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
Read Article
First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with Chronic Lymphocytic Leukemia
Wayne Kuznar
Leukemia, Hematologic Malignancies
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
Read Article
AMG 420, a Novel BiTE, Shows Impressive Responses in Heavily Treated Patients with Multiple Myeloma
Wayne Kuznar
Multiple Myeloma, Hematologic Malignancies
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
Read Article
Selinexor a Promising Oral Option in Triple-Class Refractory Multiple Myeloma
Wayne Kuznar
Multiple Myeloma
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
Read Article
Luspatercept, First-in-Class Erythroid Maturation Agent, Reduces Transfusions in Patients with Low-Risk Myelodysplastic Syndromes
Wayne Kuznar
Myelodysplastic Syndromes
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
Read Article
Daratumumab Enhances Remissions When Added to Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Wayne Kuznar
Multiple Myeloma, Hematologic Malignancies
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
Read Article
Pomalidomide Added to the Regimen in First Relapse Extends PFS in Multiple Myeloma
Wayne Kuznar
Clinical Trials, Multiple Myeloma, Hematologic Malignancies, Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected
Wayne Kuznar
Lynch Syndrome
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
NCCN Drug Affordability Ratings Miss the Mark in Lung Cancer
Wayne Kuznar
Lung Cancer, Solid Tumors, Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Cell-Free DNA Assays Could Result in a New Blood Test for Early Detection of Cancer
Wayne Kuznar
Genomic Testing
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
IMPACT: Matching Treatment and Molecular Testing Extends Survival in Advanced Cancer
Wayne Kuznar
Genomic Testing
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Immunotherapy, Multiple Myeloma, Hematologic Malignancies, Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Precision Medicine and Immunotherapy Highlighted at ASCO 2018
Wayne Kuznar
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Expanding Treatment Options for Patients with Advanced Cholangiocarcinoma
Wayne Kuznar
Cholangiocarcinoma
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Read Article
NCCN Panel Debates Cancer Care in Value-Based Healthcare Models
Wayne Kuznar
NCCN Annual Conference, Value in Oncology
Web Exclusives
Read Article
New Multiple Myeloma Guideline Assigns Preferred Regimens for Primary, Maintenance Therapy
Wayne Kuznar
Multiple Myeloma, NCCN Guidelines, Hematologic Malignancies
Web Exclusives
Read Article
Expert Panel Tackles Merits of End Points in Castrate-Resistant Prostate Cancer: Impact on Treatment and Coverage Decisions
Wayne Kuznar
AVBCC Special Feature, Prostate Cancer
Web Exclusives
Read Article
NCCN Issues First Guideline for Immunotherapy-Related Adverse Events
Wayne Kuznar
NCCN Guidelines, Side-Effects Management
Web Exclusives
Read Article
Immunotherapy Combination Shows Durable Responses in Mismatch Repair–Deficient Metastatic Colorectal Cancer
Wayne Kuznar
Colorectal Cancer, Immunotherapy, Solid Tumors, Personalized Medicine
Web Exclusives
Read Article
Daratumumab Therapy for Smoldering Myeloma Extends Progression-Free Survival
Wayne Kuznar
Drug Updates, Multiple Myeloma, Hematologic Malignancies
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Read Article
Lenalidomide plus Elotuzumab Maintenance Regimen Improves Responses in Multiple Myeloma
Wayne Kuznar
ASH 2017, Multiple Myeloma, Hematologic Malignancies, ASH Highlights
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Read Article
Ibrutinib plus Venetoclax Combo Elicits Impressive Responses in Relapsed Chronic Lymphocytic Leukemia
Wayne Kuznar
Leukemia, Hematologic Malignancies
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Read Article
Novel TKI Leads to Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia
Wayne Kuznar
Immunotherapy, Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Read Article
CAR T-Cell Therapy Shows “Impressive” Results in Multiple Myeloma
Wayne Kuznar
Hematologic Malignancies, Immunotherapy, Multiple Myeloma, Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Read Article
Quizartinib Combinations Show High Activity in Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation
Wayne Kuznar
Emerging Therapies, Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Read Article
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
Emerging Therapies, Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Read Article
First-in-Class Sotatercept Improves Hemoglobin Levels in Anemic Patients with Myelofibrosis
Wayne Kuznar
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Read Article
Precision Medicine and Immunotherapy Highlighted at ASH 2017
Wayne Kuznar
ASH 2017, ASH Highlights
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Read Article
Identifying Correct Molecular Target Essential for Treating Non–Small-Cell Lung Cancer
Wayne Kuznar
Value in Oncology
December 2017, Vol 8, No 5
Read Article
Community Oncology Is Key in Ensuring Access to Cancer Care
Wayne Kuznar
AVBCC Special Feature
December 2017, Vol 8, No 5
Read Article
Big Data in Cancer Research and Precision Medicine
Wayne Kuznar
AVBCC Special Feature
December 2017, Vol 8, No 5
Read Article
Uncertainty Clouds the Affordable Care Act: Cost-Sharing Subsidies, CHIP on the Block
Wayne Kuznar
AVBCC Special Feature
December 2017, Vol 8, No 5
Read Article
Maintenance Treatment in Mantle-Cell Lymphoma Extends Survival
Wayne Kuznar
Hematologic Malignancies, Lymphoma
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Read Article
Osimertinib Extends Progression-Free Survival in EGFR T790M–Positive Lung Cancer with CNS Metastases
Wayne Kuznar
Lung Cancer, Solid Tumors, Personalized Medicine
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Read Article
Olaparib First PARP Inhibitor to Show Advantage in BRCA-Positive Breast Cancer
Wayne Kuznar
Breast Cancer, Solid Tumors, Personalized Medicine
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Read Article
CAR T-Cell Immunotherapy Makes Strides in Multiple Myeloma, with Durable Remission
Wayne Kuznar
Multiple Myeloma, Hematologic Malignancies
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Read Article
Abiraterone a Game-Changer in the Frontline Treatment of Metastatic Prostate Cancer
Wayne Kuznar
Prostate Cancer, Solid Tumors, Personalized Medicine
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Read Article
In Chronic Myeloid Leukemia, Selection of Tyrosine Kinase Inhibitors Depends on Variables Other Than Survival
Wayne Kuznar
Leukemia, Hematologic Malignancies
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Read Article
Cediranib-Based Combination Therapy Extends Progression-Free Survival in Relapsed Ovarian Cancer
Wayne Kuznar
Emerging Therapies, Personalized Medicine
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Read Article
ASCO President Lists Progress Made in Cancer, Highlighting Current Priorities
Wayne Kuznar
Cancer Care, Personalized Medicine
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Read Article
Letermovir Prophylaxis After Transplant for Cytomegalovirus
Wayne Kuznar
Emerging Therapies, Personalized Medicine
June 2017, Vol 8, No 3
Read Article
Immunotherapy-Related Adverse Reactions: Grading of Symptoms Key to Appropriate Management
Wayne Kuznar
Immunotherapy, Personalized Medicine
June 2017, Vol 8, No 3
Read Article
Updated NCCN Guideline for Neuroendocrine Tumors and Carcinoid Syndrome Features New Therapies
Wayne Kuznar
NCCN Conference Highlights, NCCN Guidelines, Policies & Guidelines
June 2017, Vol 8, No 3
Read Article
NCCN Lung Cancer Guidelines: Combinations May Be the Future of Immunotherapy
Wayne Kuznar
Immunotherapy, NCCN Conference Highlights, Personalized Medicine
June 2017, Vol 8, No 3
Read Article
Clinical Pathways Cut Costs of Care in Non–Small-Cell Lung Cancer While Preserving Survival Rates
Wayne Kuznar
Value in Oncology
June 2017, Vol 8, No 3
Read Article
NCCN Recommends Biomarker Testing for All Patients with Newly Diagnosed NSCLC
Wayne Kuznar
NCCN Conference Highlights
June 2017, Vol 8, No 3
Read Article
Anti-CD19 CAR T-Cell Therapy After Stem-Cell Transplantation Effective in Advanced Multiple Myeloma
Wayne Kuznar
Emerging Therapies, Personalized Medicine
April 2017, Vol 8, No 2
Read Article
New Long-Acting Interferon Effective and Safe in Polycythemia Vera
Wayne Kuznar
Emerging Therapies, Personalized Medicine
April 2017, Vol 8, No 2
Read Article
CAR-Targeting CD22 an Effective Salvage Therapy in Relapsed Pediatric Acute Lymphoblastic Leukemia
Wayne Kuznar
Emerging Therapies, Personalized Medicine
April 2017, Vol 8, No 2
Read Article
Carfilzomib Maintenance Improves Response in Relapsed Multiple Myeloma After Transplant
Wayne Kuznar
Multiple Myeloma, Hematologic Malignancies
April 2017, Vol 8, No 2
Read Article
Concurrent EGFR and BRAF Inhibition Prolongs PFS in BRAF V600 Mutation–Positive Colorectal Cancer
Wayne Kuznar
GI Cancers Symposium
April 2017, Vol 8, No 2
Read Article
Cisplatin Added to Standard Regimen Leads to Unprecedented Response Rate in Patients with Stage IV Pancreatic Cancer
Wayne Kuznar
GI Cancers Symposium
April 2017, Vol 8, No 2
Read Article
Reduced-Dose Sorafenib with Uptitration in Hepatocellular Carcinoma Is Cost-Saving Without Compromising Outcome
Wayne Kuznar
GI Cancers Symposium
April 2017, Vol 8, No 2
Read Article
Lenalidomide Maintenance Therapy Extends Progression-Free Survival in Patients with High-Risk Chronic Lymphocytic Leukemia
Wayne Kuznar
Leukemia
February 2017, Vol 8, No 1
Read Article
Elotuzumab-Based Triplet Regimen Stops Progression of High-Risk Smoldering Multiple Myeloma
Wayne Kuznar
Hematologic Malignancies, Multiple Myeloma
February 2017, Vol 8, No 1
Read Article
Venetoclax plus Bortezomib and Dexamethasone Produces High Responses in Patients with Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Hematologic Malignancies, Multiple Myeloma
February 2017, Vol 8, No 1
Read Article
Brentuximab Vedotin Improves Responses Lasting 4 Months in Cutaneous T-Cell Lymphoma
Wayne Kuznar
Lymphoma
February 2017, Vol 8, No 1
Read Article
Pembrolizumab Produces Durable Responses in Relapsed or Refractory Cutaneous T-Cell Lymphoma
Wayne Kuznar
Lymphoma
February 2017, Vol 8, No 1
Read Article
Employers Look to Manage the Benefits of Specialty Pharmacy
Wayne Kuznar
Employers’ Perspective, Specialty Pharmacy, Value Peer-spectives
December 2016, Vol 7, No 11
Read Article
Cost, Access, and Delivery Challenge New Oncology Drug Options
Wayne Kuznar
Economics & Value, Value in Oncology
December 2016, Vol 7, No 11
Read Article
Value-Based Oncology Management and Outcomes-Based Contracting
Wayne Kuznar
Economics & Value, Value in Oncology
December 2016, Vol 7, No 11
Read Article
Cost-Savings Measures Will Dot the Oncology Landscape
Wayne Kuznar
Value in Oncology
December 2016, Vol 7, No 11
Read Article
ASCO CEO Addresses Quest for Value in Cancer Care
Wayne Kuznar
Economics & Value, Value in Oncology
December 2016, Vol 7, No 11
Read Article
Quality Measures Are Key to Supporting Drug Value
Wayne Kuznar
Economics & Value, Value in Oncology
December 2016, Vol 7, No 11
Read Article
Cancer Treatment Costs and Trends Beckon Risk-Sharing Future
Wayne Kuznar
Economics & Value, Value in Oncology
December 2016, Vol 7, No 11
Read Article
PhRMA’s Perspective on Value-Driven Healthcare
Wayne Kuznar
Value in Oncology
December 2016, Vol 7, No 11
Read Article
Practice Transformation Essential to the Oncology Care Model
Wayne Kuznar
Integrated Care Models
December 2016, Vol 7, No 11
Read Article
Genomic Assays Expediting Adoption of Personalized Cancer Therapy in Clinical Practice
Wayne Kuznar
Personalized Medicine
December 2016, Vol 7, No 11
Read Article
Specialty Pharmacies Add Value in the Management of Cancer Drugs
Wayne Kuznar
December 2016, Vol 7, No 11
Read Article
Maximizing the Potential of Immunotherapy the Focus of Cancer Moonshot 2020
Wayne Kuznar
Immunotherapy, Personalized Medicine
December 2016, Vol 7, No 11
Read Article
AVBCC Sixth Annual Conference: The Evolution of Value-Based Cancer Care
Wayne Kuznar
AVBCC 2016 Summit
December 2016, Vol 7, No 11
Read Article
DCIS Score Not Cost-Effective in Selecting Patients for Adjuvant Radiation
Wayne Kuznar
Value in Oncology
October 2016, Vol 7, No 9
Read Article
Venetoclax Shows Promising Efficacy in Relapsed or Refractory Acute Myelogenous Leukemia
Wayne Kuznar
Hematologic Cancers
September 2016, Vol 7, No 8
Read Article
Targeting CD38, Isatuximab Produces Impressive Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Hematologic Malignancies, Multiple Myeloma, Personalized Medicine
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Read Article
Three-Drug Regimen with Daratumumab a New Standard of Care for Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Hematologic Malignancies, Multiple Myeloma, Personalized Medicine
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Read Article
CAR T-Cell Therapy Produces High Response Rates in Refractory B-Cell Malignancies
Wayne Kuznar
Hematologic Malignancies, Leukemia
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Read Article
Atezolizumab Could Be Start of “Seismic Shift” in Metastatic Bladder Cancer Therapy
Wayne Kuznar
Bladder Cancer, Solid Tumors
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Read Article
The Oncology Drug Pipeline Shows No Evidence of Slowing Down
Wayne Kuznar
Emerging Therapies, Personalized Medicine
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Read Article
ASCO President Addresses Quality Care Through Collective Wisdom
Wayne Kuznar
Quality Care, Value in Oncology, Policies & Guidelines
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Read Article
New Biomarker Holds Promise to Discriminate Between High-Grade and Low-Grade Prostate Cancer
Wayne Kuznar
Personalized Medicine
July 2016, Vol 7, No 6
Read Article
Palliative Care Requires a Team Approach
Wayne Kuznar
Palliative Care, Personalized Medicine
July 2016, Vol 7, No 6
Read Article
Liquid Biopsies Show High Correlation with Tissue Biopsy for Genetic Mutations
Wayne Kuznar
Personalized Medicine
July 2016, Vol 7, No 6
Read Article
Nivolumab Monotherapy Prolongs Survival in Patients with Advanced Melanoma
Wayne Kuznar
Melanoma, Solid Tumors
June 2016, Vol 7, No 5
Read Article
Minor Changes in Systemic Therapy Recommendations in NCCN Breast Cancer Guideline
Wayne Kuznar
Breast Cancer, Solid Tumors
June 2016, Vol 7, No 5
Read Article
Updated NCCN Guideline Calls for EGFR Mutations Testing in All Patients with NSCLC
Wayne Kuznar
Lung Cancer, Solid Tumors
June 2016, Vol 7, No 5
Read Article
Promising Antitumor Activity of ODM-201 in Metastatic Prostate Cancer
Wayne Kuznar
Emerging Therapies, Personalized Medicine
June 2016, Vol 7, No 5
Read Article
Entrectinib Shows Strong Activity Against a Range of Rare Solid Tumors with Molecular Abnormalities
Wayne Kuznar
Emerging Therapies, Personalized Medicine
June 2016, Vol 7, No 5
Read Article
Pembrolizumab Elicits High Response in Merkel-Cell Carcinoma
Wayne Kuznar
AACR Meeting Highlights
May 2016, Vol 7, No 4
Read Article
NCCN Evidence Blocks Help Frame Value-Based Decisions for Systemic Therapies
Wayne Kuznar
NCCN Conference Highlights
May 2016, Vol 7, No 4
Read Article
Immunotherapy Takes Center Stage in the Updated NCCN Guideline for Advanced Melanoma
Wayne Kuznar
NCCN Conference Highlights
May 2016, Vol 7, No 4
Read Article
Updated NCCN Multiple Myeloma Guideline Expands Patient Eligibility and Therapeutic Options
Wayne Kuznar
NCCN Conference Highlights
May 2016, Vol 7, No 4
Read Article
Vice President Biden Promises to Remove Political Barriers to Research, Calls for Cooperation
Wayne Kuznar
AACR Meeting Highlights
May 2016, Vol 7, No 4
Read Article
NCCN Panel Examines Impact of the Presidential Election on Cancer Care
Wayne Kuznar
NCCN Conference Highlights
May 2016, Vol 7, No 4
Read Article
Getting to Value-Based Cancer Care in the ’Omics Era Requires Data Integration
Wayne Kuznar
Value-Based Care
December 2015, Vol 6, No 11
Read Article
Urine Biopsies Detect Early Mutations in Patients with Advanced Cancers
Wayne Kuznar
Personalized Medicine
December 2015, Vol 6, No 11
Read Article
Oncology Medical Home Shows Significant Cost-Savings, Improved Care Delivery
Wayne Kuznar
Oncology Practice
December 2015, Vol 6, No 11
Read Article
Next-Generation Sequencing Propelling Forward Cancer Knowledge, Therapy
Wayne Kuznar
November 2015, Vol 6, No 10
Read Article
NCCN Incorporates Affordability Criteria in Its Clinical Guidelines to Assess Value of Cancer Therapies
Wayne Kuznar
Clinical Guidelines, NCCN Conference Highlights, Policies & Guidelines
November 2015, Vol 6, No 10
Read Article
Value Proposition of Oncology Pharmaceuticals: Drug Manufacturers Increasing Focus on Patient Support
Wayne Kuznar
Value Propositions, Value Peer-spectives
October 2015, Vol 6, No 9
Read Article
An Accountable Payment Model a “Win-Win-Win” Solution to Value-Based Care
Wayne Kuznar
Economics & Value, Value-Based Care
October 2015, Vol 6, No 9
Read Article
Oncology Medical Home Accreditation by Community Oncology Alliance Making Progress
Wayne Kuznar
September 2015, Vol 6, No 8
Read Article
Oncology Specialty Pharmacy Promotes the Coordination of Care
Wayne Kuznar
Specialty Pharmacy
September 2015, Vol 6, No 8
Read Article
Oncology Pipeline Full, and Not Just with Immunotherapies
Wayne Kuznar
Emerging Therapies, Personalized Medicine
September 2015, Vol 6, No 8
Read Article
Enzalutamide Outperforms Bicalutamide in 2 Trials of Prostate Cancer
Wayne Kuznar
Prostate Cancer, Solid Tumors
September 2015, Vol 6, No 8
Read Article
Personalized Medicine Affordability Lies in Enhanced Predictors of Response to Therapy
Wayne Kuznar
Personalized Medicine
August 2015, Vol 6, No 7
Read Article
High-Value Narrow Networks and Patient Safety Organizations the Future of Cancer Care
Wayne Kuznar
August 2015, Vol 6, No 7
Read Article
Cell Surface Amino Acid Potential as Prostate Cancer Biomarker
Wayne Kuznar
Personalized Medicine, Prostate Cancer, Solid Tumors
August 2015, Vol 6, No 7
Read Article
Lenvatinib Extends Survival in Metastatic Renal-Cell Carcinoma
Wayne Kuznar
ASCO 2015 Highlights, ASCO
July 2015, Vol 6, No 6
Read Article
The Push Toward Value-Based Payment for Oncology
Wayne Kuznar
Value in Oncology
July 2015, Vol 6, No 6
Read Article
Risk Management a Key Challenge in the New Oncology Payment Models
Wayne Kuznar
June 2015, Vol 6, No 5
Read Article
Expert Panel Discusses Quality Measures, Data Collection, and Outcomes in Oncology
Wayne Kuznar
June 2015, Vol 6, No 5
Read Article
Immunotherapy Makes Headwinds into Liver Cancer
Wayne Kuznar
ASCO 2015 Highlights, Immunotherapy, ASCO
June 2015, Vol 6, No 5
Read Article
“Data in Motion” Will Promote Patient-Centric Care Models
Wayne Kuznar
June 2015, Vol 6, No 5
Read Article
Pathways Reduce Care Variation and Cost of Care, Improve Overall Outcomes
Wayne Kuznar
Pathways
June 2015, Vol 6, No 5
Read Article
Comprehensive Genomic Profiling Enables Efficient “N of 1” Trials
Wayne Kuznar
June 2015, Vol 6, No 5
Read Article
Pathways Have the Potential to Deliver Personalized Medicine
Wayne Kuznar
Pathways
May 2015, Vol 6, No 4
Read Article
In CML, Assess Response to First-Line TKI at 3 Months
Wayne Kuznar
NCCN 2015 Updates
May 2015, Vol 6, No 4
Read Article
Many Targeted Drugs in Development for Multiple Myeloma: Monoclonal Antibodies Close to Approval
Wayne Kuznar
Multiple Myeloma, NCCN 2015 Updates
May 2015, Vol 6, No 4
Read Article
Promising Therapies in Multiple Drug Classes Being Explored for B-Cell Lymphomas
Wayne Kuznar
NCCN 2015 Updates
May 2015, Vol 6, No 4
Read Article
AVBCC 5th Conference: Continuing Challenges for Optimizing Value in Oncology
Wayne Kuznar
May 2015, Vol 6, No 4
Read Article
Updated NCCN Guideline for Prostate Cancer Allows Early Treatment with Docetaxel
Wayne Kuznar
NCCN Conference Highlights
April 2015, Vol 6, No 3
Read Article
Immune Checkpoint Blockade Shows Durable Responses in Lung and Kidney Cancers, Metastatic Melanoma
Wayne Kuznar
NCCN Conference Highlights
April 2015, Vol 6, No 3
Read Article
NCCN Issues New Smoking-Cessation Guidelines for Patients with Cancer
Wayne Kuznar
NCCN Conference Highlights
April 2015, Vol 6, No 3
Read Article
Treatment for CLL Will Incorporate More Targeted Therapies in the Near Future
Wayne Kuznar
NCCN Conference Highlights
April 2015, Vol 6, No 3
Read Article
NCCN Panel Addresses Value-Based Care in Oncology
Wayne Kuznar
Economics & Value, Economics of Cancer Care, Value-Based Care
April 2015, Vol 6, No 3
Read Article
Monitoring Response to TKI Therapy by PCR Improves Outcomes in Chronic Myeloid Leukemia
Wayne Kuznar
Hematologic Malignancies, Leukemia
March 2015, Vol 6, No 2
Read Article
Vosaroxin, a Quinolone Derivative, Extends Survival in Older Patients with Acute Myeloid Leukemia
Wayne Kuznar
Hematologic Malignancies, Leukemia
March 2015, Vol 6, No 2
Read Article
Blinatumomab Immunotherapy Attacks Minimal Residual Disease in ALL, Leads to High Rates of Complete Response
Wayne Kuznar
Hematologic Malignancies, Leukemia
March 2015, Vol 6, No 2
Read Article
Value of New Drugs for Hematologic Cancers—Improving Quality, Extending Survival
Wayne Kuznar
Economics & Value, Economics of Cancer Care, Hematologic Cancers
March 2015, Vol 6, No 2
Read Article
Cancer Support Community: Empowering Patients through Knowledge and Psychosocial Care
Wayne Kuznar
October 2014, Vol 5 , No 8
Read Article
Managing Cancer at the Workplace Enhances Productivity, Has Value for Employers
Wayne Kuznar
October 2014, Vol 5 , No 8
Read Article
Oncology Medical Home Pilot Improves Outcomes
Wayne Kuznar
October 2014, Vol 5 , No 8
Read Article
Does Comparative Effectiveness Research Have Value in Oncology?
Wayne Kuznar
Comparative Effectiveness Research
October 2014, Vol 5 , No 8
Read Article
Adding Luteinizing Hormone-Releasing Hormone Agonist to Chemotherapy Preserves Fertility in Women with Breast Cancer
Wayne Kuznar
Breast Cancer, Solid Tumors
October 2014, Vol 5 , No 8
Read Article
HER2-Derived Vaccine Cuts Recurrences in Patients with High-Risk Breast Cancer
Wayne Kuznar
Breast Cancer, Solid Tumors
October 2014, Vol 5 , No 8
Read Article
Patient-Centered Oncology Medical Home Improves Health Outcomes at Lower Costs to Patients and Payers
Wayne Kuznar
October 2014, Vol 5 , No 8
Read Article
Comparative Effectiveness Research Helps Define Value in Cancer Care
Wayne Kuznar
Comparative Effectiveness Research
September 2014, Vol 5, No 7
Read Article
Payer Challenges in Oncology: Establishing Standards and Access to Quality Care
Wayne Kuznar
September 2014, Vol 5, No 7
Read Article
Improving the Value Paradigm in Drug Development Will Require More Efficient Clinical Trials, New Biomarkers
Wayne Kuznar
September 2014, Vol 5, No 7
Read Article
Maximizing Value and Quality in Gynecologic Cancer Care—Work in Progress
Wayne Kuznar
Value in Oncology
September 2014, Vol 5, No 7
Read Article
Predictive Testing Holds More Value to Oncology Stakeholders than Prognostic Testing
Wayne Kuznar
Cancer Care
September 2014, Vol 5, No 7
Read Article
Should You Consider the Interests of Society at Large When Treating the Individual Patient?
Wayne Kuznar
Value in Oncology
September 2014, Vol 5, No 7
Read Article
Next-Generation Sequencing Provides Value to Multiple Stakeholders
Wayne Kuznar
September 2014, Vol 5, No 7
Read Article
Oncologists Can Become Value-Based Providers Using Evidence to Guide Patient Care
Wayne Kuznar
Value in Oncology, Value-Based Care
September 2014, Vol 5, No 7
Read Article
Necitumumab Extends Survival of Patients with Squamous Lung Cancer
Wayne Kuznar
Lung Cancer, Personalized Medicine, Solid Tumors
August 2014, Vol 5, No 6
Read Article
QOPI Measures Identify Areas for Quality Improvement in Oncology Practice
Wayne Kuznar
Oncology Practice
August 2014, Vol 5, No 6
Read Article
Big Data and CancerLinQ Can Help to Optimize Patient Outcomes in Oncology
Wayne Kuznar
August 2014, Vol 5, No 6
Read Article
Using IBM Watson Electronic System to Guide Patient Management in Oncology
Wayne Kuznar
Oncology Practice
August 2014, Vol 5, No 6
Read Article
Oncology Pipeline Bustling, But Value Concerns Lead to Increased Payer Scrutiny
Wayne Kuznar
August 2014, Vol 5, No 6
Read Article
Upfront Docetaxel Markedly Improves Survival
Wayne Kuznar
Personalized Medicine, Prostate Cancer, Solid Tumors
August 2014, Vol 5, No 6
Read Article
Adjuvant Exemestane More Effective than Tamoxifen in Early-Stage Breast Cancer
Wayne Kuznar
Breast Cancer, Personalized Medicine, Solid Tumors
August 2014, Vol 5, No 6
Read Article
Shifts to Value-Based Care and Payment Models Are Improving Quality of Care
Wayne Kuznar
Economics & Value, Reimbursement, Value-Based Care
August 2014, Vol 5, No 6
Read Article
Patients with Cancer Are Not Asking for Low-Value Tests or Therapies
Wayne Kuznar
Economics & Value, Economics of Cancer Care
August 2014, Vol 5, No 6
Read Article
Most Hospital Readmissions Not Preventable for Patients with Cancer
Wayne Kuznar
Economics & Value, Economics of Cancer Care
August 2014, Vol 5, No 6
Read Article
Even When Adjusting for Improved Survival, Newer Anticancer Drugs Are More Expensive than Older Ones
Wayne Kuznar
Economics & Value, Economics of Cancer Care
August 2014, Vol 5, No 6
Read Article
Patients with Cancer Need Psychosocial Support, Expression of Caring
Wayne Kuznar
August 2014, Vol 5, No 6
Read Article
2014 Oncology Pipeline Looks Impressive
Wayne Kuznar
Emerging Therapies, Personalized Medicine
August 2014, Vol 5, No 6
Read Article
Delaying ADT for PSA-Only Relapse May Be Viable Option for Men with Prostate Cancer and PSA-Only Relapses
Wayne Kuznar
ASCO 2014 Highlights, ASCO
June 2014, Vol 5, No 5
Read Article
Patients with Cancer Want but Are Not Getting Information on the Cost of Their Therapy
Wayne Kuznar
ASCO 2014 Highlights, ASCO
June 2014, Vol 5, No 5
Read Article
Worksite Pharmacies Can Enhance Overall Drug Management of Patients with Cancer
Wayne Kuznar
June 2014, Vol 5, No 5
Read Article
Worksite Health Centers Can Help Employees Manage Cancer
Wayne Kuznar
June 2014, Vol 5, No 5
Read Article
The Value of Personalized Medicine Lies in Evidence Thresholds, Drug Testing, and Pricing Trends
Wayne Kuznar
Personalized Medicine
June 2014, Vol 5, No 5
Read Article
Significant Hurdles Must Be Overcome to Actualize the Value of Personalized Medicine
Wayne Kuznar
June 2014, Vol 5, No 5
Read Article
AVBCC Expert Panel: Impact of Personalized Medicine on Future and Current Therapies
Wayne Kuznar
June 2014, Vol 5, No 5
Read Article
Treatment Paradigm for Lung Cancer Shifting Toward Targeted Therapies, Immunotherapy
Wayne Kuznar
Lung Cancer, Personalized Medicine, Solid Tumors
May 2014, Vol 5, No 4
Read Article
Advances in the Treatment of Patients with Castration-Resistant Prostate Cancer
Wayne Kuznar
Personalized Medicine, Prostate Cancer, Solid Tumors
May 2014, Vol 5, No 4
Read Article
Updated NCCN Survivorship Guidelines
Wayne Kuznar
Survivorship, Policies & Guidelines
May 2014, Vol 5, No 4
Read Article
Emerging Targeted Therapies for Advanced Pancreatic Cancer Show Promise
Wayne Kuznar
Pancreatic Cancer
May 2014, Vol 5, No 4
Read Article
Payers Facing Multiple Challenges in Ensuring Access to Cancer Care
Wayne Kuznar
May 2014, Vol 5, No 4
Read Article
AVBCC Fourth Conference: Optimizing Value and Stakeholder Integration in Cancer Care
Wayne Kuznar
May 2014, Vol 5, No 4
Read Article
Updated NCCN Melanoma Guideline Adds BRAF Inhibitor and MEK Inhibitor to First-Line Targeted Therapeutic Options
Wayne Kuznar
NCCN 2014 Conference
April 2014, Vol 5, No 3
Read Article
Updated NCCN Guidelines for Non-Hodgkin Lymphoma Note Controversy Related to B-Cell Disease Management
Wayne Kuznar
NCCN 2014 Conference, NCCN Guidelines, Policies & Guidelines
April 2014, Vol 5, No 3
Read Article
In the Real World, Bevacizumab Improves Survival in Patients with Metastatic Colorectal Cancer
Wayne Kuznar
Colorectal Cancer
April 2014, Vol 5, No 3
Read Article
Personalized Cancer Care: Combination Therapies May Be Key to Hitting Tumor Heterogeneity
Wayne Kuznar
Personalized Medicine
April 2014, Vol 5, No 3
Read Article
New Molecular Test to Monitor Breast Cancer Recurrence by Sequencing Circulating Tumor Cells
Wayne Kuznar
Personalized Medicine
April 2014, Vol 5, No 3
Read Article
Ramucirumab Improves Survival as Second-Line Therapy in Patients with Advanced Gastric Cancer
Wayne Kuznar
Gastric Cancer
April 2014, Vol 5, No 3
Read Article
Implications of the ACA for Cancer Care
Wayne Kuznar
Economics & Value, Economics of Cancer Care
April 2014, Vol 5, No 3
Read Article
Biomarker Development and Validation Crucial to Appropriate Use of Emerging Treatments in Oncology
Wayne Kuznar
Personalized Medicine
March 2014, Vol 5, No 2
Read Article
Understanding Molecular Subtypes Is Basis for Genomic Medicine in Prostate Cancer
Wayne Kuznar
Personalized Medicine
March 2014, Vol 5, No 2
Read Article
Switching from Intravenous to Subcutaneous Rituximab Saves Staff Time and Money
Wayne Kuznar
Economics & Value, Economics of Cancer Care
March 2014, Vol 5, No 2
Read Article
New Pathways, Targeted Therapies Being Explored in Hepatocellular Carcinoma
Wayne Kuznar
Pathways, Policies & Guidelines
March 2014, Vol 5, No 2
Read Article
Adjuvant Chemotherapy Benefit in Stage II Colon Cancers Is Small, May Even Cause Harm, Depending on Prognostic Markers
Wayne Kuznar
GI Cancers Symposium
February 2014, Vol 5, No 1
Read Article
Genetics Providing New Insights into Signaling Pathways and Treatment Targets in ALL
Wayne Kuznar
Personalized Medicine
February 2014, Vol 5, No 1
Read Article
Peripheral T-Cell Lymphoma Associated with High Clinical Burden, Resource Utilization, and Costs
Wayne Kuznar
2018 AONN+ Midyear Conference, Economics & Value
February 2014, Vol 5, No 1
Read Article
Significant Hospital Costs Tied to 30-Day Readmissions for Allogeneic Transplants
Wayne Kuznar
Economics & Value, Economics of Cancer Care
February 2014, Vol 5, No 1
Read Article
Rituximab Infusions Costlier When Given in the Hospital than in the Office Setting
Wayne Kuznar
Economics & Value, Economics of Cancer Care
February 2014, Vol 5, No 1
Read Article
Physicians Must Consider the Financial Burden Associated with Allogeneic Transplants
Wayne Kuznar
Economics & Value, Economics of Cancer Care
February 2014, Vol 5, No 1
Read Article
Decitabine More Cost-Effective than Conventional Induction in Older Patients with AML
Wayne Kuznar
Economics & Value, Economics of Cancer Care
February 2014, Vol 5, No 1
Read Article
Hematologic Drug Pipeline Boasts Novel Approaches
Wayne Kuznar
Emerging Therapies, Personalized Medicine
February 2014, Vol 5, No 1
Read Article
Next-Generation Sequencing Identifies “Actionable” Genomic Alterations in Solid Tumors
Wayne Kuznar
Personalized Medicine
November 2013, Vol 4, No 9
Read Article
Practical Problems Must Be Overcome to Move Personalized Medicine Forward in Oncology
Wayne Kuznar
Personalized Medicine
November 2013, Vol 4, No 9
Read Article
Bronchial/Nasal Gene-Expression Tests for Early Detection of Lung Cancer
Wayne Kuznar
Personalized Medicine
November 2013, Vol 4, No 9
Read Article
Redesigning Clinical Trials Necessary to Enhance Discovery of Effective Targeted Drugs in the Genomic Era
Wayne Kuznar
Personalized Medicine
October 2013, Vol 4, No 8
Read Article
Emerging Therapies and New Approaches in the “Double-Refractory” Setting in Myeloma
Wayne Kuznar
Drug Updates, Emerging Therapies, Personalized Medicine
September 2013, Vol 4, No 7
Read Article
Chemotherapy-Induced Neuropathy Can Persist a Decade after Stopping Treatment for Colorectal Cancer
Wayne Kuznar
Drug Updates
September 2013, Vol 4, No 7
Read Article
New Technologies Bring No Upward Shift in Treatment of Local Prostate Cancer
Wayne Kuznar
Personalized Medicine, Prostate Cancer, Solid Tumors
September 2013, Vol 4, No 7
Read Article
Causes for Hospital Readmissions of Patients with Cancer
Wayne Kuznar
Economics & Value, Economics of Cancer Care
September 2013, Vol 4, No 7
Read Article
Poor Adherence to Oral Cancer Drugs a Growing Concern
Wayne Kuznar
Economics & Value, Economics of Cancer Care
September 2013, Vol 4, No 7
Read Article
Mammography Screening Rates Enhanced by Copay Elimination
Wayne Kuznar
Economics & Value, Economics of Cancer Care
September 2013, Vol 4, No 7
Read Article
ASCO President Highlights Bridges to Conquer Cancer
Wayne Kuznar
Economics & Value, Economics of Cancer Care
July 2013, Vol 4, No 6
Read Article
Use of High-Cost Tests for Lung Cancer Surveillance Rising
Wayne Kuznar
Economics & Value, Economics of Cancer Care
June 2013, Vol 4, No 5
Read Article
Bevacizumab an Effective New Treatment Option for Relapsed Cervical Cancer
Wayne Kuznar
ASCO Annual Meeting, ASCO
June 2013, Vol 4, No 5
Read Article
Variations in Cancer Treatment Raise Average Cost of Care by $25,000 per Patient
Wayne Kuznar
ASCO Annual Meeting, ASCO
June 2013, Vol 4, No 5
Read Article
Ruxolitinib Treatment Reduces Myelofibrosis Symptoms, Spleen Size
Wayne Kuznar
ASH 2013 Annual Meeting
February 2013, Vol 4, No 2
Read Article
Ponatinib Produces High Response Rates in Hard-to-Treat Leukemia
Wayne Kuznar
ASH 2013 Annual Meeting
January 2013, Vol 4, No 1
Read Article
Quality of Life Drives Patient Preference for Metastatic Renal-Cell Carcinoma Drug
Wayne Kuznar
ASCO Annual Meeting, ASCO
July 2012, Vol 3, No 5
Read Article
Tivozanib Outperforms Sorafenib as First-Line Treatment in Advanced Renal-Cell Carcinoma
Wayne Kuznar
ASCO Annual Meeting, ASCO
July 2012, Vol 3, No 5
Read Article
Cancer Screening Saves Lives, Is Cost-Effective
Wayne Kuznar
ASCO Annual Meeting, ASCO
July 2012, Vol 3, No 5
Read Article
Unforeseen Hospital Admissions Are Frequent for Patients Receiving Radiotherapy
Wayne Kuznar
ASCO Annual Meeting, ASCO
July 2012, Vol 3, No 5
Read Article
In Head-to-Head Comparison, Continuous Beats Intermittent Hormonal Therapy for Metastatic Prostate Cancer
Wayne Kuznar
ASCO Annual Meeting, ASCO
June 2012, Vol 3, No 4
Read Article
External Beam Radiation More Toxic, Costlier than Brachytherapy or Prostatectomy
Wayne Kuznar
Genitourinary Cancers Symposium
March 2012, Vol 3, No 2
Read Article
Personalized Vaccine Promising When Added to Sunitinib in Patients with Metastatic Renal-Cell Carcinoma
Wayne Kuznar
Genitourinary Cancers Symposium
March 2012, Vol 3, No 2
Read Article
Dose Escalation of Axitinib as Second-Line Treatment of mRCC May Be Needed to Optimize Outcome
Wayne Kuznar
Genitourinary Cancers Symposium
March 2012, Vol 3, No 2
Read Article
Many Patients with mRCC Ineligible for Clinical Trials
Wayne Kuznar
Genitourinary Cancers Symposium
March 2012, Vol 3, No 2
Read Article
Comparative Effectiveness Analysis of 3 Radiation Therapies for Prostate Cancer
Wayne Kuznar
Genitourinary Cancers Symposium
February 2012, Vol 3, No 1
Read Article
The Impact of Therapy Type on Clinical Fragmentation in Oncology Care
Wayne Kuznar
Oncology
July 2011, Vol 2, No 4
Read Article
Medical and Pharmacy Directors’ Strategies to Improve Cancer Care Management
Wayne Kuznar
Cancer Care, Personalized Medicine
July 2011, Vol 2, No 4
Read Article
Oncology Pharmacy as a Specialty
Wayne Kuznar
Oncology
July 2011, Vol 2, No 4
Read Article
Oncology Drug Reimbursement and Administration Benchmarks
Wayne Kuznar
Reimbursement
July 2011, Vol 2, No 4
Read Article
Patient Navigation and Patient Assistance Programs in Oncology
Wayne Kuznar
Patient Navigation, Policies & Guidelines
July 2011, Vol 2, No 4
Read Article
Community Oncology Clinics under Increasing Financial Pressure
Wayne Kuznar
Community Oncology, Economics & Value
July 2011, Vol 2, No 4
Read Article
A New Option for Metastatic Breast Cancer
Wayne Kuznar
Breast Cancer, Personalized Medicine, Solid Tumors
July 2011, Vol 2, No 4
Read Article
The Age of Personalized Oncology Therapies
Wayne Kuznar
Personalized Medicine
July 2011, Vol 2, No 4
Read Article
NCCN Guidelines Inform Decisions Across the Continuum of Cancer Care
Wayne Kuznar
NCCN Guidelines, Policies & Guidelines
July 2011, Vol 2, No 4
Read Article
Benefit Design Trends in Oncology Management
Wayne Kuznar
Oncology Benefit Edition
July 2011, Vol 2, No 4
Read Article
The Role of Molecular Diagnostics in Cancer Treatment
Wayne Kuznar
Cancer Care, Personalized Medicine
July 2011, Vol 2, No 4
Read Article
Payer Trends in Oncology: Challenges and Solutions
Wayne Kuznar
AVBCC Annual Conference
July 2011, Vol 2, No 4
Read Article
Value-Based Insurance Design in Oncology
Wayne Kuznar
Economics & Value, Value in Oncology, Value-Based Care
July 2011, Vol 2, No 4
Read Article

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.